Palforzia® Oral Immunotherapy for Peanut Allergy Now Available for U.S. Children Aged 1-3

Palforzia® Oral Immunotherapy for Peanut Allergy Now Available for U.S. Children Aged 1-3 Stallergenes Greer Launches Palforzia® for Peanut Allergy in U.S. Toddlers Aged 1-3 Stallergenes Greer, a global leader in allergy therapeutics, has announced the launch of Palforzia® [Peanut…

Read MorePalforzia® Oral Immunotherapy for Peanut Allergy Now Available for U.S. Children Aged 1-3

Astoria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenivart for HAE

Astoria Therapeutics Launches ALPHA-ORBIT Phase 3 Trial for Navenivart in Hereditary Angioedema Astoria Therapeutics, a biopharmaceutical company focused on developing breakthrough therapies for allergy and immunology disorders, has announced the initiation of the ALPHA-ORBIT trial, a pivotal Phase 3 clinical…

Read MoreAstoria Therapeutics Launches Phase 3 ALPHA-ORBIT Trial of Navenivart for HAE
PhosAgro Increases Shipments to Africa

PhosAgro Increases Shipments to Africa by 33% and Expands Soil Protection Initiatives in 2024

PhosAgro Increases Fertilizer Supplies to Africa by One Third in 2024, Expands Soil Protection Initiatives PhosAgro, one of the world’s largest producers of phosphate-based fertilizers, made significant strides in increasing its presence in Africa. The company successfully raised its fertilizer…

Read MorePhosAgro Increases Shipments to Africa by 33% and Expands Soil Protection Initiatives in 2024